| Profiling Approach | Caris Molecular Intelligence®[8-18] | FoundationOne®[20,24,25,26,27,29,30,31,32,33,34,37,40,41,42] | PCDxTM45 | |||
| n | (%) | n | (%) | n | (%) | |
| Overall Number of Patients | 385 | - | 302 | - | 19 | - |
| Chemotherapy alone | 271 | (70) | 5 | (2) | 2 | (11) |
| Chemotherapy plus hormone therapy | 5 | (1) | 0 | - | 0 | - |
| Chemotherapy plus targeted therapy | 63 | (16) | 24 | (8) | 3 | (16) |
| Targeted Therapy alone | 30 | (8) | 202 | (67) | 9 | (47) |
| Hormone therapy alone | 12 | (3) | 2 | (<1) | 0 | - |
| Targeted therapy plus hormone therapy | 3 | (<1) | 11 | (4) | 0 | - |
| Immunotherapy alone | 1 | (<1) | 6 | (2) | 2 | (11) |
| Investigational agents | 0 | - | 52 | (17) | 3 | (16) |
| Monotherapy | 143 | (37) | 225 | (75) | 13 | (68) |
| Combination therapy | 242 | (63) | 77 | (25) | 6 | (32) |